knowledge -WSS

knowledge

author：fashion 2025-09-14 18:33:23 - browse：3

Ionis Pharmaceuticals, a California biotech that has spearheaded the development of RNA-targeting medicines, announced on Tuesday that its drug against familial chylomicronemia syndrome, a rare and serious disease that prevents the body from breaking down fats, succeeded in a late-stage clinical trial.

The Phase 3 trial, dubbed Balance, enrolled 66 adults who were randomly divided into three groups and given a monthly injection of placebo or one of two doses of olezarsen, the company’s experimental drug. Treatment with the higher dose of the therapy significantly lowered triglycerides in the blood of those on the drug for six months compared to participants given placebo, though a lower dose did not have this effect. Participants on the high dose didn’t have any instances of painful inflammation of the pancreas, one of the disease’s most serious symptoms, while there were 11 such episodes among those on placebo.

Researchers reported that the treatment was also generally safe, with fewer adverse events among those on olezarsen than among the placebo group.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Tesla recalling nearly 16,000 of its 2021

WSS

Lawsuit highlights wrinkle for disputes over surprise medical bills

Indian pharmaceutical industry in denial over drug

Public funding for King Charles III and royals has been recalculated due to windfarm deal profits

Health insurers' Q3 question: how much care are people getting?

The stability of $0 premiums in Medicare Advantage

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

Wikipedia

knowledge

hotspot

Medical records are filled with copy

Hospitals struggle to profit from CAR

ChatGPT in medicine: STAT answers readers' burning questions

Public funding for King Charles III and royals has been recalculated due to windfarm deal profits

How one medical school became remarkably diverse

Will an HIV vaccine ever be a reality?

Novavax promises a turnaround & Lilly roils the obesity market

What we owe ALS patients — and why one company fell short

At least 13 dead in Texas as scorching temps continue

The stability of $0 premiums in Medicare Advantage

Wikipedia

Mass General totes up its waste in a move to tackle climate change

Tocagen's brain cancer gene therapy trial continues. Investors worry

Flu, Covid vaccination rates decline, new survey data show

Key lawmaker blasts Congress’ efforts on addiction: ‘Shame on us’

Texas Department of Public Safety speaks out on migrant abuse allegations

EF3 tornado rips through North Carolina amid extreme weather nationwide

explore

focus

explore

hotspot